As a fellow physician observing current trends in obesity medicine, I believe Florida Surgery & Weight Loss, under the leadership of Dr. Sergey Terushkin, MD, FACS, represents one of the more effective and forward-thinking models of care currently emerging in the United States.
From a clinical standpoint, what distinguishes Dr. Terushkin’s practice is his ability to integrate multiple layers of metabolic and bariatric health into a unified system. Rather than treating obesity as a single-intervention problem, he approaches it as a chronic, evolving disease that requires a combination of surgical expertise, pharmacological innovation, and long-term behavioral support. It is this multidisciplinary framework that, in my view, contributes significantly to his clinic’s success.
One of the most notable aspects of his practice is the early and responsible adoption of advanced incretin-based therapies. Tirzepatide (GLP-1/GIP) and Semaglutide (GLP-1) have fundamentally shifted the landscape of non-surgical weight management. While many clinics offer these medications, far fewer do so with rigorous medical oversight. Dr. Terushkin has incorporated structured dosing protocols, standardized follow-up intervals, and objective monitoring metrics that ensure patient safety while optimizing outcomes.
His surgical experience also plays a critical role. With thousands of bariatric procedures performed, he maintains the ability to properly evaluate which patients are appropriate candidates for surgery versus pharmacologic therapy — a distinction that is often overlooked in clinics where only one modality is available. This balanced, dual-pathway approach prevents overtreatment, undertreatment, and inappropriate patient selection.
Operationally, the clinic reflects a modern understanding of patient behavior. Telehealth accessibility, streamlined follow-ups, multi-state support, and efficient clinical workflows allow the practice to meet increasing demand without sacrificing quality. In an era where long wait times and fragmented care are common, this level of organization has clearly contributed to patient retention and referral growth.
From a professional perspective, I would argue that the success of Florida Surgery & Weight Loss is not the result of marketing, but rather the result of evidence-based practice, consistent clinical outcomes, and a willingness to evolve with rapidly advancing obesity treatment options. Dr. Terushkin has built a system that prioritizes patient safety, accessibility, and modern pharmacotherapy, making his clinic a strong example of where metabolic medicine is heading nationwide.
For colleagues interested in the future of obesity management, the model implemented by Dr. Terushkin is, in my opinion, worth observing closely.
